Bromocriptine

Roehrich, H; Dackis, Charles A.; Gold, Mark S.

doi:10.1002/med.2610070206

Cited by 24 publications

(10 citation statements)

References 254 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, the relevance that these experimental findings have on the present and future use of bromocriptine in the treatment of Parkinson's disease will be explored. The use of bromocriptine in a variety of clinical states such as cocaine abuse, hyperprolactinaemia, depression and acromegaly, amongst others, has recently been reviewed in detail from the therapeutic perspective by Roehrich et al (1987) and will not be discussed here.…”

Section: Introductionmentioning

confidence: 99%

The motor effects of bromocriptine ? a review

1988

View full text Add to dashboard Cite

For many years, bromocriptine has proven to be a useful treatment for some of the disabling motor effects seen in Parkinson's disease. As such, it has been the only commonly used directly acting D2 agonist available. But its mechanism of action has been obscure because many animal models indicated an absolute requirement for the presence of endogenous DA for bromocriptine to have any efficacy, despite its undoubted occupation of the D2 receptor with high affinity. Several scattered reports indicated, however, that bromocriptine could potentiate the effects of a number of other dopamine agonists (such as apomorphine and L-dopa) in a variety of pharmacological models and in the clinic. With the availability of SKF38393 and SCH23390, it soon became clear that bromocriptine, while a selective D2 agonist, depended in an absolute sense on the integrity of the D1 receptors. Thus, if SKF38393 was administered together with bromocriptine to rodents depleted of dopamine, marked locomotor excitation was produced, despite either drug alone being inactive. The present review explores the literature on the motor effects of bromocriptine and endeavours to integrate its behavioural, biochemical and electrophysiological effects into a coherent whole. It closes with a consideration of several remaining unsolved problems associated with the pharmacology of bromocriptine and suggests some future studies.

show abstract

Section: Introductionmentioning

confidence: 99%

The motor effects of bromocriptine ? a review

1988

View full text Add to dashboard Cite

show abstract

“…A number of pharmacologic trials for treatment of cocaine dependence have focused on dopamine agonists 10–17 . Bromocriptine has been compared with placebo in several trials involving cocaine‐dependent patients.…”

mentioning

confidence: 99%

A Comparison of Pergolide and Bromocriptine in the Initial Rehabilitation of Cocaine Dependence

et al. 1994

View full text Add to dashboard Cite

Numerous pharmacologic agents have been used in an attempt to improve treatment outcome for cocaine‐dependent individuals. In this study, 41 men and women newly admitted to a 30‐day inpatient treatment program for cocaine dependence were randomized to open treatment with pergolide or bromocriptine (two dopamine agonists) or a no‐medication group. Treatment groups were compared for mean length of stay in the hospital (MLS), number of discharges against medical advice (AMA), and on a self‐report visual analog craving scale prior to treatment and again between Day 7 and Day 10. The pergolide and bromocriptine groups both had an MLS of 25 days, with one AMA discharge (6%). The no‐medication treatment group had an MLS of 16.2 days and four (36%) AMA discharges. Mean decrease in the craving scores in the pergolide group was 31.8, in the bromocriptine group, 24.0, and in the no‐medication group, 7.9.

show abstract

“…Forty-one consecutive cocaine-dependent admissions to a private chemical dependency treatment facility were randomized to either pergolide (n = 151, bromocriptine (n = 151, or no-medication (n- 11) treatment in an open-label fashion. Subjects were black and white men and non-pregnant women between the ages of 21 and 50, enrolled in a %-day inpatient program.…”

Section: Methodsmentioning

confidence: 99%

A Comparison of Pergolide and Bromocriptine in the Initial Rehabilitation of Cocaine Dependence

Malcolm¹,

Phillips²,

Brady³

et al. 1994

Am J Addict

View full text Add to dashboard Cite

Numerouspharmacologic agents haw been lLsed in an attempt to itnpmw tmatment ouc~ome for cocaine-dqxdmt individuals. In this study, 41 men and umnen newly admitted to a 3CMay inpatient treatment program for cocaine a k p d e m e were randomized to open treatment with pergolide or bromocriptine (tum dopamine agonists) or a no-medication group. Tmatmmtgmups were compamdfor mean length of stay in the hospital (W), number of discharges against medical advice (AMA), and on a serf-mport visual analog craving scale prior to treatment and again between Day 7 and Day 10. The pergolide and hmocriptine groups both had an MLS of ZS days, with one AMA discharge 6%). % no-medication treatment group had an MLS of 16.2 days and four (36%) AMA discharges. Mean &crease in the craving scorn in the-olide group was 31.8, in the bnnnocriptine gmup, 24.0, and in the no-medication group, 7.9. (American Journal on Addictions 1994; 3:144-150) here have been promising advances in T the use of pharmacologic agents for the treatment of cocaine dependence. In some of the earliest pharmacologic trials, Gawin and colleagues' found the tricyclic antidepressant desipramine to be more effective and than placebo in promoting short-term abstinence (6 weeks) in cocaine-dependent subjects. In meta-analysis of six placebocontrolled trials of the use of desipramine in cocaine-dependent subjects, no significant difference in treatment retention rates be-

show abstract

Bromocriptine

Cited by 24 publications

References 254 publications

The motor effects of bromocriptine ? a review

The motor effects of bromocriptine ? a review

A Comparison of Pergolide and Bromocriptine in the Initial Rehabilitation of Cocaine Dependence

A Comparison of Pergolide and Bromocriptine in the Initial Rehabilitation of Cocaine Dependence

Contact Info

Product

Resources

About